Alopecia Areata: From Immunopathogenesis to Emerging Therapeutic Approaches

In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8⁺ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This study highlights the role of immune dysregulation, microRNA modulation, and SIRT1 pathways in alopecia areata, suggesting antisense oligonucleotides targeting miR-485-3p as a promising therapeutic strategy for promoting hair regrowth and reducing inflammation in murine models.

This study evaluated eight JAK inhibitor regimens for alopecia areata and provided high-quality evidence on their comparative effectiveness, which can aid clinicians in decision-making and inform medical practice guidelines.

This study found that transgenic mice overexpressing IKZF1 developed lesions similar to alopecia areata, suggesting that Ikaros may play a role in the disease's pathogenesis. Ikaros expression was also higher in human alopecia areata patients compared to controls.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found that PPARα agonists provided protective effects in mouse models of alopecia areata by promoting early reversal of the condition and inhibiting T effector cell function, indicating potential therapeutic value for this inflammatory condition.

This study found that patients with alopecia areata exhibited higher ratios of neutrophils-to-lymphocytes and eosinophils-to-lymphocytes compared to controls, suggesting potential markers for disease prediction and management.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

In this animal study, researchers found that local administration of mesenchymal stem cell therapy improved hair regrowth and reduced local inflammatory cytokines in mice with Alopecia Areata, although systemic cytokine levels were unchanged.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This study identified distinct immune differences in patients with alopecia areata, particularly those with atopic backgrounds, and highlighted the OX40 axis as a potential therapeutic target for the condition.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This study observed that dupilumab may promote hair regrowth in alopecia areata patients, achieving significant results in a majority of cases without reported adverse events.

This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

In this study using a mouse model and human data, researchers found that CD8+ T cells are central to driving alopecia areata, while regulatory T cells offer some protection, highlighting CD8+ T cells as key targets for future therapy development.

This research found that reduced expression of SIRT1 in human scalp tissue may contribute to alopecia areata development by inducing immune-inflammatory responses in hair follicle cells, suggesting that SIRT1 plays a regulatory role in hair follicle immunity.

This article discusses the role of regulatory T cells in alopecia areata, where their deficiency in hair follicles may lead to impaired local immunity and suggests potential therapies like CAR-T reg cells and low-dose IL-2 to alleviate autoimmunity and promote hair regeneration in affected individuals.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.

This review discusses the challenges in identifying specific hair follicle antigens involved in initiating alopecia areata and highlights the need for further research to understand its etiopathogenesis, reporting no new results.

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

In this study, Nec-1s was found to promote hair growth and may target necroptosis and the Wnt/β-catenin pathway for potential treatment of hair loss.

This pilot study suggests that skin-resident γδT-cells may play a significant role in the early stages of alopecia areata pathogenesis, indicating a potential new target for therapeutic management.

This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.

This study found that T-regulatory cells, specifically the FOXP3 CD39 subset, were significantly reduced in both circulation and hair follicles of alopecia areata patients compared to healthy subjects, suggesting potential therapeutic targets.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.

In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.

This study found that the Stem Cell Educator therapy improved hair regrowth and quality of life in patients with severe alopecia areata by restoring immune balance and protecting hair follicles from autoimmune damage.

This review summarizes the current genetic research on alopecia areata, including potential new therapeutic strategies, but reports no new clinical findings.

This study found that plasmacytoid dendritic cells are central to the pathogenesis of alopecia areata, suggesting they may help differentiate it from trichotillomania and androgenetic alopecia.

Eosinophilic infiltrate is not a reliable indicator for diagnosing chronic alopecia areata.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

The study suggests that vaccination with soluble keratin peptides K71 and K31 significantly delayed the onset and progression of autoimmune alopecia areata in mice by inducing T cell anergy.

Other common signs, not just the well-known immune cells around hair bulbs, are important for diagnosing hair loss from alopecia areata.

This study suggests that an immune response to trichohyalin and keratin 16 may contribute to the pathogenesis of alopecia areata.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.

Ebastine may help regrow hair in alopecia areata patients.

This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.

In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.

Alopecia areata is an autoimmune disorder causing hair loss, linked to specific hair follicle antigens and genetic factors.

This study found that PPAR alpha, -delta, and -gamma are expressed in human hair follicle cells, and clofibrate exhibited a beneficial effect on hair follicle survival in culture within a specific concentration range.

Eosinophils are not a reliable marker for diagnosing alopecia areata.

This study found that eosinophils are a useful diagnostic feature for alopecia areata, especially when the typical "swarm of bees" lymphoid infiltrate is absent, helping differentiate it from trichotillomania.